open access

Vol 88, No 9 (2017)
Review paper
Published online: 2017-09-29
Get Citation

Perspectives for the pharmacological treatment of overactive bladder syndrome

Andrzej Wróbel1, Tomasz Kluz2, Grzegorz Surkont3, Edyta Wlaźlak3, Paweł Miotła1, Katarzyna Skorupska1, Tomasz Rechberger1
DOI: 10.5603/GP.a2017.0092
·
Pubmed: 29057437
·
Ginekol Pol 2017;88(9):504-508.
Affiliations
  1. Second Department of Gynecology, Medical University of Lublin,, Jaczewskiego 8, PL 20-090 Lublin, Poland, 20-090 Lublin, Poland
  2. Department of Obstetrics and Gynecology, Fryderyk Chopin University Hospital No 1, Faculty of Medicine, Rzeszow University, Chopina 2, PL 35-055 Rzeszów, Poland, 35-055 Rzeszów, Poland
  3. Department of Operative Gynecology and Gynecologic Oncology, Ist Department of Gynecology and Obstetrics, Medical University of Łódź, Wileńska 37, 94-029 Łódź, Poland, 94-029 Łódź, Poland

open access

Vol 88, No 9 (2017)
REVIEW PAPERS Gynecology
Published online: 2017-09-29

Abstract

It has been found that antimuscarinic drugs, viewed as the “gold standard” in overactive bladder syndrome (OAB) treatment, have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for new options in OAB pharmacotherapy. The conducted pre-clinical trials have led to the development of new solutions for the treatment of OAB, which stand a good chance of being applied in clinical practice. The said compounds are characterised by higher receptor and organ specificity than currently used medications.

Abstract

It has been found that antimuscarinic drugs, viewed as the “gold standard” in overactive bladder syndrome (OAB) treatment, have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for new options in OAB pharmacotherapy. The conducted pre-clinical trials have led to the development of new solutions for the treatment of OAB, which stand a good chance of being applied in clinical practice. The said compounds are characterised by higher receptor and organ specificity than currently used medications.

Get Citation

Keywords

overactive bladder syndrome, pharmacotherapy, detrusor overactivity

About this article
Title

Perspectives for the pharmacological treatment of overactive bladder syndrome

Journal

Ginekologia Polska

Issue

Vol 88, No 9 (2017)

Article type

Review paper

Pages

504-508

Published online

2017-09-29

DOI

10.5603/GP.a2017.0092

Pubmed

29057437

Bibliographic record

Ginekol Pol 2017;88(9):504-508.

Keywords

overactive bladder syndrome
pharmacotherapy
detrusor overactivity

Authors

Andrzej Wróbel
Tomasz Kluz
Grzegorz Surkont
Edyta Wlaźlak
Paweł Miotła
Katarzyna Skorupska
Tomasz Rechberger

References (13)
  1. Leone Roberti Maggiore U, Scala C, Venturini PL, et al. Imidafenacin for the treatment of overactive bladder. Expert Opin Pharmacother. 2013; 14(10): 1383–1397.
  2. Song M, Kim JH, Lee KS, et al. The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study. Int J Clin Pract. 2015; 69(2): 242–250.
  3. Dmochowski RR, Staskin DR, Duchin K, et al. Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder. Int J Clin Pract. 2014; 68(8): 986–994.
  4. Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012; 62(5): 834–840.
  5. Janicki JJ, Chancellor MB, Kaufman J, et al. Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction. Toxins (Basel). 2016; 8(3).
  6. Di Rezze S, Frasca V, Inghilleri M, et al. Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study. Clin Neuropharmacol. 2012; 35(5): 231–234.
  7. Carbone A, Palleschi G, Conte A, et al. Gabapentin treatment of neurogenic overactive bladder. Pharmacol Exp Therap. 2014; 350: 543–551.
  8. Lecci A, Maggi CA. Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept. 2001; 101(1-3): 1–18.
  9. Merrill L, Vizzard MA. Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats. Am J Physiol Regul Integr Comp Physiol. 2014; 307(4): R471–R480.
  10. Tyagi V, Philips BJ, Su R, et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol. 2009; 181(4): 1932–1938.
  11. Wróbel A, Rechberger T. The Influence of Maxacalcitol, Vitamin D3 Analog, on Detrusor Overactivity in Conscious Rats. Urology. 2016; 93: 224.e7–224.e15.
  12. Lecci A, Giuliani S, Meini S, et al. Nociceptin and the micturition reflex. Peptides. 2000; 21(7): 1007–1021.
  13. Rechberger T, Nowakowski Ł, Rechberger E, et al. Prevalence of common comorbidities among urogynaecological patients. Ginekol Pol. 2016; 87(5): 342–346.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl